Premium
Clofarabine salvage therapy for refractory high‐risk langerhans cell histiocytosis
Author(s) -
Abraham Allistair,
Alsultan Abdulrahman,
Jeng Michael,
RodriguezGalindo Carlos,
Campbell Patrick K.
Publication year - 2013
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24436
Subject(s) - clofarabine , medicine , salvage therapy , refractory (planetary science) , langerhans cell histiocytosis , cladribine , toxicity , cytarabine , oncology , chemotherapy , disease , physics , astrobiology
Pediatric patients with refractory multisystem Langerhans cell histiocytosis (LCH) have a poor prognosis despite aggressive chemotherapy. Salvage therapy with cytarabine and cladribine has shown promise as an effective treatment but is associated with significant toxicity. A previous report described two patients with refractory LCH who had a rapid response to single‐agent clofarabine with minimal toxicity. In this report, we describe four children with refractory, risk‐organ‐positive LCH who were treated with clofarabine and provide follow‐up for the two previously reported cases. The results support development of a formal trial evaluating clofarabine as front‐line salvage for refractory LCH. Pediatr Blood Cancer 2013; 60: E19–E22. © 2012 Wiley Periodicals, Inc.